A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

A GSK medicine that was pulled from the market after failing its confirmatory test in multiple myeloma has new data from a Phase 3 study evaluating it as an earlier line of treatment, and the ...

SAN DIEGO — Omitting 24-hour urine testing from multiple myeloma response assessments does not compromise accurate tracking of patients' responses to treatment, a new analysis indicates.